JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/50/0.1/16.01.26 | Market Closed - Börse Stuttgart 05:28:59 2024-06-28 EDT | ||
| 0.3 EUR | -9.09% |
|
| Current month | +11.11% | ||
| 1 month | +3.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.3 | -9.09% |
| 24-06-27 | 0.33 | +3.13% |
| 24-06-25 | 0.32 | -.--% |
| 24-06-24 | 0.32 | +10.34% |
| 24-06-21 | 0.29 | +3.57% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 05:28 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK63PY |
| ISIN | DE000JK63PY1 |
| Date issued | 2024-04-12 |
| Strike | 50 $ |
| Maturity | 2026-01-16 (565 Days) |
| Parity | 10 : 1 |
| Emission price | 0.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.69 € |
|---|---|
| Lowest since issue | 0.26 € |
| Spread | 0.02 € |
| Spread % | 6.45% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.53
USD
Average target price
53.19
USD
Spread / Average Target
+28.09%
- Stock Market
- Warrants
- Warrant
